Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375367 | 0.86 | CYP1A2 (0.42) | CNR1CNR2PDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL6098200 | 0.85 | CYP3A4 (0.41) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL1663614 | 0.79 | TRIM24 (0.46) | SMN1; SMN2KDM4ELMNAPOLBMEN1 | |
| SCHEMBL29923830 | 0.79 | KDM4E (0.41) | SMN1; SMN2KDM4ELMNAPOLBMEN1 | |
| SCHEMBL29923693 | 0.79 | TRIM24 (0.46) | SMN1; SMN2KDM4ELMNAPOLBMEN1 | |
| SCHEMBL24915825 | 0.79 | KDM4E (0.41) | SMN1; SMN2KDM4ELMNAPOLBMEN1 | |
| SCHEMBL11195737 | 0.77 | KDM4E (0.52) | SMN1; SMN2KDM4ELMNAPOLBMEN1 | |
| SCHEMBL24916024 | 0.77 | CNR1 (0.41) | CNR1CNR2SMN1; SMN2KDM4ELMNA | |
| SCHEMBL30950666 | 0.76 | SMN1; SMN2 (0.43) | CNR1CNR2PIK3CDSMN1; SMN2TP53 | |
| SCHEMBL6096600 | 0.76 | SMN1; SMN2 (0.43) | CNR1CNR2PIK3CDSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303026-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20140179709-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-06-26 | — | — | US | disclosed |
| US-8624025-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-01-07 | — | — | US | disclosed |
| US-20130005736-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-03 | — | — | US | disclosed |
| US-8217171-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20110212966-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-7951955-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-05-31 | — | — | US | disclosed |
| EP-2314582-A1 | Heterocyclic compounds as antiviral agents | Biota Scientific Management Pty Ltd (AU) | 2011-04-27 | — | — | EP | disclosed |
| US-7829705-B2 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2010-11-09 | — | — | US | disclosed |
| US-7579465-B2 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGMENT PTY. LTD. (AU) | 2009-08-25 | — | — | US | disclosed |
| US-20090030000-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2009-01-29 | — | — | US | disclosed |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-7166604-B2 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-01-23 | — | — | US | disclosed |
| EP-1353911-A4 | ANTIVIRAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2005-01-05 | — | — | EP | disclosed |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2004-04-22 | — | — | US | disclosed |
| EP-1353911-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002050045-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | HAVCR2, EIF2AK2, MAVS | CNR1 4042/4885CNR2 4557/4885PIK3CD 4502/4885 |
| US-20090030000-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CNR1 4564/4885CNR2 4836/4885PIK3CD 2257/4885 |
| US-20130005736-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CNR1 4564/4885CNR2 4836/4885PIK3CD 2257/4885 |
| US-20110212966-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CNR1 4564/4885CNR2 4836/4885PIK3CD 2257/4885 |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | EIF2AK2, IFNAR1, HAVCR2 | CNR1 238/4885CNR2 734/4885PIK3CD 3502/4885 |
| US-20140179709-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CNR1 4564/4885CNR2 4836/4885PIK3CD 2257/4885 |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | RNASEH1, RPL35, SARS1 | CNR1 1935/4885CNR2 3496/4885PIK3CD 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.